NOVARTIS AG
NVSEFDrugs in Pipeline
276
Phase 3 Programs
169
Upcoming Catalysts
13
Next Catalyst
This month
Market Overview
Stock performance and key metrics
13 upcoming, 0 past
TOUR006 - 20 MG Phase 2 Est. Readout
Estimated primary completion for TOUR006 - 20 MG trial (NCT06088979) in Thyroid Eye Disease. Topline data typically follows completion by weeks to months.
SourceYTB323 Phase 2 Est. Readout
Primary completion for YTB323 trial (NCT05798117) in Systemic Lupus Erythematosus
Source11 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Indacaterol 150 µg
Chronic Obstructive Pulmonary Disease (COPD)
Certoparin
Renal Dialysis
Inclisiran
Atherosclerotic Cardiovascular Disease
Alpelisib
Breast Neoplasms
ACZ885
Pulmonary Sarcoidosis
asciminib
Chronic Myelogenous Leukemia - Chronic Phase
Everolimus (RAD001)
Renal Transplantation
Lansoprazole
Frequent Heartburn
Aliskiren/HCTZ
Hypertension
Pimecrolimus Cream 1%
Chronic Hand Dermatitis
Canakinumab 150 mg
Type 2 Diabetes Mellitus
Triamcinolone acetonide 40 mg
Acute Gout
Telbivudine (LdT)
Chronic Hepatitis B
VAY736
Sjogren Syndrome
Certican
Kidney Transplantation
Vildagliptin AM
Diabetes Mellitus, Type 2
terbinafine
Onychomycosis
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Non-Hodgkin Lymphoma
Monovalent A/H1N1 influenza vaccine
Pandemic Influenza
CTL019
Acute Lymphoblastic Leukemia
imatinib mesylate
Leukemia
deferasirox
Non-transfusion Dependent Thalassemia
Ranibizumab 0.5 mg
Proliferative Diabetic Retinopathy (PDR)
telbivudine
Chronic Hepatitis B
Meningococcal C Conjugate Vaccine
Prevention of Meningococcal Infection
RLX030
Acute Heart Failure
secukinumab (AIN457)
Rheumatoid Arthritis
Ianalumab
Primary Immune Thrombocytopenia (ITP)
Olmesartan medoxomil
Hypertension
trivalent split influenza vaccine
Seasonal Influenza
Focalin XR
ADHD
Everolimus + reduced tacrolimus
Liver Transplantation
Octreotide
Acromegaly
Pelacarsen
Atherosclerotic Cardiovascular Disease (ASCVD)
rMenB+OMV
Meningococcal Disease
Lamivudine
Chronic Hepatitis B
ciclosporin
Severe Atopic Dermatitis
Enteric-Coated Mycophenolate Sodium
Prevention of Acute Rejection After Kidney Transplantation
Pimecrolimus
Keratoconjunctivitis Sicca
MenACWY-CRM
Meningococcal Disease
LCQ908
Familial Chylomicronemia Syndrome (FCS)
Darifenacin
Overactive Bladder Syndrome
Vatalanib
Colorectal Neoplasms
Serogroup B meningococcal vaccine
Meningococcal Disease
rivastigmine transdermal patch
Alzheimer's Disease
Pasireotide
Cushing's Disease
Indacaterol 150 μg
Chronic Obstructive Pulmonary Disease (COPD)
Myfortic
Kidney Transplantation
Capmatinib
Non-Small Cell Lung Cancer (NSCLC)
Umeclidinium/vilanterol
Chronic Obstructive Pulmonary Disease
terbinafine hydrogen chloride
Onychomycosis
Octreotide LAR
Acromegaly
Agomelatine (AGO178C)
Major Depressive Disorder
osilodrostat
Cushings Disease
Ofatumumab
Relapsing Multiple Sclerosis
LCZ696
Hypertension
Meningococcal ACWY conjugate vaccine
Bacterial Meningitis
Fingolimod 1.25 mg
Multiple Sclerosis
Physicians' Choice
Leukaemia
ranibizumab 0.5mg
Choroidal Neovascularisation
Olmesartan
Essential Hypertension
Siponimod
Multiple Sclerosis (MS)
oxcarbazepine
Epilepsy
RTH258/Brolucizumab
Neovascular Age Related Macular Degeneration
Diclofenac sodium gel 1%
Osteoarthritis
zigakibart
Kidney Diseases
Ranibizumab (RFB002)
Diabetic Macular Edema
Dabrafenib
Neoplasms, Brain
valsartan + amlodipine
Hypertension
BKM120
HER2-positive Newly Diagnosed, Primary Breast Cancer
Gliclazide
Diabetes Mellitus, Type 2
Secukinumab 300 mg
Chronic Scalp Psoriasis
Salmeterol 50 μg
Chronic Obstructive Pulmonary Disease
AIN457
Plaque-type Psoriasis
Valsartan/amlodipine 80/5 mg
Hypertension
iptacopan
IC-MPGN
rMenB+OMV NZ
Prevention of the Meningococcal Disease
Brolucizumab
Diabetic Macular Edema
Seasonal Influenza Vaccine
Influenza
valsartan/amlodipine
Hypertension
Panobinostat
Cutaneous T-Cell Lymphoma
Tiotropium 18 μg
Chronic Obstructive Pulmonary Disease (COPD)
Fluvastatin
Mixed Dyslipidemia
Inclisiran sodium 300 mg
Atherosclerotic Cardiovascular Disease
Haemophilus influenzae type b (Hib) vaccine
Haemophilus Influenzae Type b (Hib) Infection
NIS793
Metastatic Pancreatic Ductal Adenocarcinoma
Verteporfin Photodynamic Therapy
Macular Degeneration
MenACWY-CRM197
Meningitis
vildagliptin + metformin
Diabetes Mellitus, Type 2
Basiliximab
Liver Transplant
Indacaterol 300 µg
Chronic Obstructive Pulmonary Disease (COPD)
BION-1301
IgA Nephropathy
LNP023
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ruxolitinib
Cytokine Storm (Covid-19)
Ligelizumab
Chronic Spontaneous Urticaria
AMN107
Leukemia, Myeloid, Chronic
QAB149
Chronic Obstructive Pulmonary Disease (COPD)
Tobramycin inhalation powder
Pulmonary Infections
LOU064
Chronic Spontaneous Urticaria
Bosutinib
Chronic Myelogenous Leukemia
Amlodipine
Hypertension; Hypertrophy, Left Ventricular
pazopanib
Renal Cell Carcinoma (RCC)
valsartan plus hydrochlorothiazide
Hypertension
Ceritinib
Non-Small Cell Lung Cancer
indacaterol maleate
Pulmonary Disease, Chronic Obstructive
Omalizumab (Xolair)
Chronic Urticaria
Hydroxycarbamide
Polycythemia Vera
Ribociclib 200Mg Oral Tablet
Breast Cancer Female
MF59-eH1N1_f
Influenza
Glycopyrronium bromide
Chronic Obstructive Pulmonary Disease
Fingolimod
Multiple Sclerosis
dovitinib
Solid Tumors
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Swine-Origin Influenza A H1N1 Virus
Influenza virus vaccine
Influenza
Enalapril
Hypertension
secukinumab 150 mg
Moderate to Severe Chronic Plaque-type Psoriasis
Rivastigmine
Vascular Dementia
Indacaterol 300 μg
Chronic Obstructive Pulmonary Disease
Formoterol
Chronic Obstructive Pulmonary Disease
Mycophenolate mofetil (MMF)
Kidney Transplantation
Secukinumab (75 mg)
Psoriatic Arthritis
Formoterol (12 µg b.i.d.)
Pulmonary Disease, Chronic Obstructive
Nilotinib (AMN107)
Gastrointestinal Stromal Tumor (GIST)
NVA237
Chronic Obstructive Pulmonary Disease
Lapatinib
Breast Neoplasms
LCZ696 (Sacubitril/Valsartan)
Chronic Heart Failure With Reduced Ejection Fraction
Cyclosporine
Severe Aplastic Anemia
QVA149
Chronic Obstructive Pulmonary Disease (COPD)
vildagliptin
Diabetes Mellitus, Type 2
ranibizumab
Neovascular Age-related Macular Degeneration
TIVc
Influenza
Omalizumab
Asthma
QVM149
Asthma
secukinumab
Juvenile Psoriatic Arthritis
Tegaserod
Dyspepsia
Tisagenlecleucel
Follicular Lymphoma (FL)
aliskiren
Hypertension
Indacaterol
Asthma
Zoledronic acid
Breast Cancer With Bone Metastasis
Tiotropium
Chronic Obstructive Pulmonary Disease (COPD)
ramipril
Heart Failure
inclisiran sodium
Hypercholesterolemia
Mycophenolate sodium (enteric coated)
Renal Transplant
Canakinumab pre-filled syringe
Acute Gouty Arthritis
Diclofenac topical sodium gel 1%
Osteoarthritis
Pelabresib
Myelofibrosis
Ribociclib
Breast Cancer
sacubitril/valsartan
Heart Failure
TQJ230
Cardiovascular Disease and Lipoprotein(a)
Trametinib
Melanoma and Brain Metastases
Pasireotide LAR
Acromegaly
RAD001
Carcinoma
QAW039
Asthma
Lumiracoxib
Knee Osteoarthritis
Licarbazepine
Bipolar Disorder
Onasemnogene Abeparvovec-xioi
Spinal Muscular Atrophy Type I
Canakinumab
Rheumatoid Arthritis
Enteric-coated Mycophenolate sodium (EC-MPS)
Liver Transplantation
Artemether-lumefantrine
Plasmodium Falciparum Malaria
Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Valsartan
Hypertension
FTY720
Multiple Sclerosis
Teriflunomide
Relapsing Multiple Sclerosis
eltrombopag
Immune Thrombocytopenic Purpura (ITP)
Erenumab
Episodic Migraine
agomelatine
Major Depressive Disorder (MDD)
Diclofenac Sodium
Acute Ankle Sprain
Salmeterol
Asthma
Famciclovir
Herpes Labialis
Sandostatin LAR Depot
Primary Insulin Hypersecretion
LFG316
Neovascular Age-elated Macular Degeneration (Wet AMD)
indacaterol/glycopyrrolate
Chronic Obstructive Pulmonary Disease (COPD)
inhaled corticosteroid therapy
Bronchial Asthma
Aliskiren 300 mg
Post Acute Coronary Syndrome
Spartalizumab
Advanced Hepatocellular Carcinoma
SAF312
Chronic Ocular Pain
TIP
Non-cystic Fibrosis Bronchiectasis
Midostaurin
Acute Myeloid Leukemia
INC424
Primary Myelofibrosis
Iptacopan (LNP023)
Age-Related Macular Degeneration
Adjuvanted influenza vaccine
Influenza Disease
BAF312
Relapsing Remitting Multiple Sclerosis
Eltrombopag 12.5 mg
Cytopaenia
TOUR006 - 50 MG
Chronic Kidney Diseases
LYS006
Hidradenitis Suppurativa
Nidufexor
Diabetic Nephropathy
MAS825
Coronary Heart Disease
DNK333 5 mg
Pruritus in Patients With Atopic Dermatitis
ECMPS-IEM
Detection Accuracy
MCS110
Triple Negative Breast Cancer
influenza vaccine
Influenza
QAX576
Allergic Rhinitis
LCI699
Hypertension
LYS006 20 mg
Inflammatory Acne
AEE788
Glioblastoma Multiforme
Cryptosporidium parvum oocysts (ABO809)
Cryptosporidiosis
AQW051
Schizophrenia
Clozapine
Schizophrenia
HSC835
Single Umbilical Cord Blood Transplantation
QMF149
COPD
DFV890
Symptomatic Knee Osteoarthritis
TCH346
Amyotrophic Lateral Sclerosis
CAD106
Alzheimer Disease
Trivalent influenza virus vaccine (TIV)
Human Influenza
TIV
Human Influenza
LDK378
Non-Small-Cell Lung Cancer
DNK333
Irritable Bowel Syndrome
rapcabtagene autoleucel
Lupus Erythematosus, Systemic
Tacrolimus (Tac)
Kidney Transplantation
Serelaxin
Acute Heart Failure
AF056
Fragile X Syndrome
AHU377
Systolic Hypertension
LDE225
Medulloblastoma
LIK066
Polycystic Ovary Syndrome
LEE011
Tumors With CDK4/6 Pathway Activation
CMK389
Pulmonary Sarcoidosis
Investigational Treatment
Actinic Keratosis
AEB071
Kidney Transplantation
crizanlizumab
Sickle Cell Disease (SCD)
TKI258
Melanoma
LDE225 0.25%
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
CDZ173
Primary Sjögren's Syndrome
AAE581
Osteoporosis
Mometasone furoate
Asthma
Monovalent inactivated influenza vaccine
Prepandemic Influenza Vaccine
Seasonal flu vaccine
Seasonal Influenza
Triamcinolone acetonide
Acute Gout
Investigational new drug, company code: BGG492
Seizures
PKN605
Atrial Fibrillation
rapcabtagene autoleucel (YTB323)
Relapsing Multiple Sclerosis
Deferasirox (ICL670)
Iron Overload
Atrasentan
IgA Nephropathy
AFQ056
Dyskinesias
YTB323
Systemic Lupus Erythematosus
TOUR006 - 20 MG
Thyroid Eye Disease
TIN816 70 mg lyophilisate powder
Acute Kidney Injury Due to Sepsis
N-acetylcysteine
Common Cold Associated With Cough
epothilone b
Colorectal Neoplasms
ICL670
Sickle Cell Disease
buparlisib
Breast Cancer
JSB462
Metastatic Hormone-sensitive Prostate Cancer
JDQ443
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Everolimus and Intravesical Gemcitabine
Bladder Cancer
H5N1 influenza vaccine
Avian Influenza
PTK787
Prostate Cancer
QCZ484
Hypertension (HTN)
AUY922
Relapsed or Refractory Multiple Myeloma
bimagrumab
Muscle Wasting (Atrophy) After Hip Fracture Surgery
[177Lu]Lu-PSMA-617
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
KAE609
Malaria
SBR759
Chronic Kidney Disease
Investigator choice of chemotherapy
Nasopharyngeal Carcinoma
LAG525
Melanoma
STI571
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Surface Antigen, Inactivated, Influenza (form.2006-07)
Influenza
QGE031
Asthma
BYM338
Sporadic Inclusion Body Myositis
CJM112
Asthma
LCL161
Breast Cancer
CFZ533
Sjögren Syndrome
BGG492
Adrenocortical Adenoma
Dovitinib (TKI258)
Gastrointestinal Stromal Tumors
GIA632
Non-segmental Vitiligo
rMenB
Meningococcal Disease
Patupilone
Hepatocellular Carcinoma
QBW251
Chronic Obstructive Pulmonary Disease, COPD
DJI136
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
AIN457A
Psoriatic Arthritis
Crizanlizuamb
Sickle Cell Disease (SCD)
RAD001 (everolimus)
Small Cell Lung Cancer
PDR001
Small Cell Lung Cancer
VHB937
Alzheimer's Disease
KAF156
Malaria
Gleevec
Prostate Cancer
LHW090
Chronic Kidney Disease (CKD)
Adjuvanted H5N1 pandemic influenza vaccine
Pandemic H5N1 Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Indacaterol 150 µg | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Certoparin | Phase 3 | Renal Dialysis | - | - |
Inclisiran | Phase 3 | Atherosclerotic Cardiovascular Disease | - | - |
Alpelisib | Phase 3 | Breast Neoplasms | - | - |
ACZ885 | Phase 3 | Pulmonary Sarcoidosis | - | - |
asciminib | Phase 3 | Chronic Myelogenous Leukemia - Chronic Phase | - | - |
Everolimus (RAD001) | Phase 3 | Renal Transplantation | - | - |
Lansoprazole | Phase 3 | Frequent Heartburn | - | - |
Aliskiren/HCTZ | Phase 3 | Hypertension | - | - |
Pimecrolimus Cream 1% | Phase 3 | Chronic Hand Dermatitis | - | - |
Canakinumab 150 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Triamcinolone acetonide 40 mg | Phase 3 | Acute Gout | - | - |
Telbivudine (LdT) | Phase 3 | Chronic Hepatitis B | - | - |
VAY736 | Phase 3 | Sjogren Syndrome | - | - |
Certican | Phase 3 | Kidney Transplantation | - | - |
Vildagliptin AM | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
terbinafine | Phase 3 | Onychomycosis | - | - |
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy | Phase 3 | Non-Hodgkin Lymphoma | - | - |
Monovalent A/H1N1 influenza vaccine | Phase 3 | Pandemic Influenza | - | - |
CTL019 | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
imatinib mesylate | Phase 3 | Leukemia | - | - |
deferasirox | Phase 3 | Non-transfusion Dependent Thalassemia | - | - |
Ranibizumab 0.5 mg | Phase 3 | Proliferative Diabetic Retinopathy (PDR) | - | - |
telbivudine | Phase 3 | Chronic Hepatitis B | - | - |
Meningococcal C Conjugate Vaccine | Phase 3 | Prevention of Meningococcal Infection | - | - |
RLX030 | Phase 3 | Acute Heart Failure | - | - |
secukinumab (AIN457) | Phase 3 | Rheumatoid Arthritis | - | - |
Ianalumab | Phase 3 | Primary Immune Thrombocytopenia (ITP) | - | - |
Olmesartan medoxomil | Phase 3 | Hypertension | - | - |
trivalent split influenza vaccine | Phase 3 | Seasonal Influenza | - | - |
Focalin XR | Phase 3 | ADHD | - | - |
Everolimus + reduced tacrolimus | Phase 3 | Liver Transplantation | - | - |
Octreotide | Phase 3 | Acromegaly | - | - |
Pelacarsen | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD) | - | - |
rMenB+OMV | Phase 3 | Meningococcal Disease | - | - |
Lamivudine | Phase 3 | Chronic Hepatitis B | - | - |
ciclosporin | Phase 3 | Severe Atopic Dermatitis | - | - |
Enteric-Coated Mycophenolate Sodium | Phase 3 | Prevention of Acute Rejection After Kidney Transplantation | - | - |
Pimecrolimus | Phase 3 | Keratoconjunctivitis Sicca | - | - |
MenACWY-CRM | Phase 3 | Meningococcal Disease | - | - |
LCQ908 | Phase 3 | Familial Chylomicronemia Syndrome (FCS) | - | - |
Darifenacin | Phase 3 | Overactive Bladder Syndrome | - | - |
Vatalanib | Phase 3 | Colorectal Neoplasms | - | - |
Serogroup B meningococcal vaccine | Phase 3 | Meningococcal Disease | - | - |
rivastigmine transdermal patch | Phase 3 | Alzheimer's Disease | - | - |
Pasireotide | Phase 3 | Cushing's Disease | - | - |
Indacaterol 150 μg | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Myfortic | Phase 3 | Kidney Transplantation | - | - |
Capmatinib | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
Umeclidinium/vilanterol | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
terbinafine hydrogen chloride | Phase 3 | Onychomycosis | - | - |
Octreotide LAR | Phase 3 | Acromegaly | - | - |
Agomelatine (AGO178C) | Phase 3 | Major Depressive Disorder | - | - |
osilodrostat | Phase 3 | Cushings Disease | - | - |
Ofatumumab | Phase 3 | Relapsing Multiple Sclerosis | - | - |
LCZ696 | Phase 3 | Hypertension | - | - |
Meningococcal ACWY conjugate vaccine | Phase 3 | Bacterial Meningitis | - | - |
Fingolimod 1.25 mg | Phase 3 | Multiple Sclerosis | - | - |
Physicians' Choice | Phase 3 | Leukaemia | - | - |
ranibizumab 0.5mg | Phase 3 | Choroidal Neovascularisation | - | - |
Olmesartan | Phase 3 | Essential Hypertension | - | - |
Siponimod | Phase 3 | Multiple Sclerosis (MS) | - | - |
oxcarbazepine | Phase 3 | Epilepsy | - | - |
RTH258/Brolucizumab | Phase 3 | Neovascular Age Related Macular Degeneration | - | - |
Diclofenac sodium gel 1% | Phase 3 | Osteoarthritis | - | - |
zigakibart | Phase 3 | Kidney Diseases | - | - |
Ranibizumab (RFB002) | Phase 3 | Diabetic Macular Edema | - | - |
Dabrafenib | Phase 3 | Neoplasms, Brain | - | - |
valsartan + amlodipine | Phase 3 | Hypertension | - | - |
BKM120 | Phase 3 | HER2-positive Newly Diagnosed, Primary Breast Cancer | - | - |
Gliclazide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Secukinumab 300 mg | Phase 3 | Chronic Scalp Psoriasis | - | - |
Salmeterol 50 μg | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
AIN457 | Phase 3 | Plaque-type Psoriasis | - | - |
Valsartan/amlodipine 80/5 mg | Phase 3 | Hypertension | - | - |
iptacopan | Phase 3 | IC-MPGN | - | - |
rMenB+OMV NZ | Phase 3 | Prevention of the Meningococcal Disease | - | - |
Brolucizumab | Phase 3 | Diabetic Macular Edema | - | - |
Seasonal Influenza Vaccine | Phase 3 | Influenza | - | - |
valsartan/amlodipine | Phase 3 | Hypertension | - | - |
Panobinostat | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Tiotropium 18 μg | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Fluvastatin | Phase 3 | Mixed Dyslipidemia | - | - |
Inclisiran sodium 300 mg | Phase 3 | Atherosclerotic Cardiovascular Disease | - | - |
Haemophilus influenzae type b (Hib) vaccine | Phase 3 | Haemophilus Influenzae Type b (Hib) Infection | - | - |
NIS793 | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
Verteporfin Photodynamic Therapy | Phase 3 | Macular Degeneration | - | - |
MenACWY-CRM197 | Phase 3 | Meningitis | - | - |
vildagliptin + metformin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Basiliximab | Phase 3 | Liver Transplant | - | - |
Indacaterol 300 µg | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
BION-1301 | Phase 3 | IgA Nephropathy | - | - |
LNP023 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
Ruxolitinib | Phase 3 | Cytokine Storm (Covid-19) | - | - |
Ligelizumab | Phase 3 | Chronic Spontaneous Urticaria | - | - |
AMN107 | Phase 3 | Leukemia, Myeloid, Chronic | - | - |
QAB149 | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Tobramycin inhalation powder | Phase 3 | Pulmonary Infections | - | - |
LOU064 | Phase 3 | Chronic Spontaneous Urticaria | - | - |
Bosutinib | Phase 3 | Chronic Myelogenous Leukemia | - | - |
Amlodipine | Phase 3 | Hypertension; Hypertrophy, Left Ventricular | - | - |
pazopanib | Phase 3 | Renal Cell Carcinoma (RCC) | - | - |
valsartan plus hydrochlorothiazide | Phase 3 | Hypertension | - | - |
Ceritinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
indacaterol maleate | Phase 3 | Pulmonary Disease, Chronic Obstructive | - | - |
Omalizumab (Xolair) | Phase 3 | Chronic Urticaria | - | - |
Hydroxycarbamide | Phase 3 | Polycythemia Vera | - | - |
Ribociclib 200Mg Oral Tablet | Phase 3 | Breast Cancer Female | - | - |
MF59-eH1N1_f | Phase 3 | Influenza | - | - |
Glycopyrronium bromide | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Fingolimod | Phase 3 | Multiple Sclerosis | - | - |
dovitinib | Phase 3 | Solid Tumors | - | - |
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine | Phase 3 | Swine-Origin Influenza A H1N1 Virus | - | - |
Influenza virus vaccine | Phase 3 | Influenza | - | - |
Enalapril | Phase 3 | Hypertension | - | - |
secukinumab 150 mg | Phase 3 | Moderate to Severe Chronic Plaque-type Psoriasis | - | - |
Rivastigmine | Phase 3 | Vascular Dementia | - | - |
Indacaterol 300 μg | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Formoterol | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Mycophenolate mofetil (MMF) | Phase 3 | Kidney Transplantation | - | - |
Secukinumab (75 mg) | Phase 3 | Psoriatic Arthritis | - | - |
Formoterol (12 µg b.i.d.) | Phase 3 | Pulmonary Disease, Chronic Obstructive | - | - |
Nilotinib (AMN107) | Phase 3 | Gastrointestinal Stromal Tumor (GIST) | - | - |
NVA237 | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Lapatinib | Phase 3 | Breast Neoplasms | - | - |
LCZ696 (Sacubitril/Valsartan) | Phase 3 | Chronic Heart Failure With Reduced Ejection Fraction | - | - |
Cyclosporine | Phase 3 | Severe Aplastic Anemia | - | - |
QVA149 | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
vildagliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
ranibizumab | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
TIVc | Phase 3 | Influenza | - | - |
Omalizumab | Phase 3 | Asthma | - | - |
QVM149 | Phase 3 | Asthma | - | - |
secukinumab | Phase 3 | Juvenile Psoriatic Arthritis | - | - |
Tegaserod | Phase 3 | Dyspepsia | - | - |
Tisagenlecleucel | Phase 3 | Follicular Lymphoma (FL) | - | - |
aliskiren | Phase 3 | Hypertension | - | - |
Indacaterol | Phase 3 | Asthma | - | - |
Zoledronic acid | Phase 3 | Breast Cancer With Bone Metastasis | - | - |
Tiotropium | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
ramipril | Phase 3 | Heart Failure | - | - |
inclisiran sodium | Phase 3 | Hypercholesterolemia | - | - |
Mycophenolate sodium (enteric coated) | Phase 3 | Renal Transplant | - | - |
Canakinumab pre-filled syringe | Phase 3 | Acute Gouty Arthritis | - | - |
Diclofenac topical sodium gel 1% | Phase 3 | Osteoarthritis | - | - |
Pelabresib | Phase 3 | Myelofibrosis | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
sacubitril/valsartan | Phase 3 | Heart Failure | - | - |
TQJ230 | Phase 3 | Cardiovascular Disease and Lipoprotein(a) | - | - |
Trametinib | Phase 3 | Melanoma and Brain Metastases | - | - |
Pasireotide LAR | Phase 3 | Acromegaly | - | - |
RAD001 | Phase 3 | Carcinoma | - | - |
QAW039 | Phase 3 | Asthma | - | - |
Lumiracoxib | Phase 3 | Knee Osteoarthritis | - | - |
Licarbazepine | Phase 3 | Bipolar Disorder | - | - |
Onasemnogene Abeparvovec-xioi | Phase 3 | Spinal Muscular Atrophy Type I | - | - |
Canakinumab | Phase 3 | Rheumatoid Arthritis | - | - |
Enteric-coated Mycophenolate sodium (EC-MPS) | Phase 3 | Liver Transplantation | - | - |
Artemether-lumefantrine | Phase 3 | Plasmodium Falciparum Malaria | - | - |
Pelacarsen (TQJ230) | Phase 3 | Cardiovascular Disease and Lipoprotein(a) | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
FTY720 | Phase 3 | Multiple Sclerosis | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - | - |
eltrombopag | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - | - |
Erenumab | Phase 3 | Episodic Migraine | - | - |
agomelatine | Phase 3 | Major Depressive Disorder (MDD) | - | - |
Diclofenac Sodium | Phase 3 | Acute Ankle Sprain | - | - |
Salmeterol | Phase 3 | Asthma | - | - |
Famciclovir | Phase 3 | Herpes Labialis | - | - |
Sandostatin LAR Depot | Phase 2 | Primary Insulin Hypersecretion | - | - |
LFG316 | Phase 2 | Neovascular Age-elated Macular Degeneration (Wet AMD) | - | - |
indacaterol/glycopyrrolate | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
inhaled corticosteroid therapy | Phase 2 | Bronchial Asthma | - | - |
Aliskiren 300 mg | Phase 2 | Post Acute Coronary Syndrome | - | - |
Spartalizumab | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
SAF312 | Phase 2 | Chronic Ocular Pain | - | - |
TIP | Phase 2 | Non-cystic Fibrosis Bronchiectasis | - | - |
Midostaurin | Phase 2 | Acute Myeloid Leukemia | - | - |
INC424 | Phase 2 | Primary Myelofibrosis | - | - |
Iptacopan (LNP023) | Phase 2 | Age-Related Macular Degeneration | - | - |
Adjuvanted influenza vaccine | Phase 2 | Influenza Disease | - | - |
BAF312 | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Eltrombopag 12.5 mg | Phase 2 | Cytopaenia | - | - |
TOUR006 - 50 MG | Phase 2 | Chronic Kidney Diseases | - | - |
LYS006 | Phase 2 | Hidradenitis Suppurativa | - | - |
Nidufexor | Phase 2 | Diabetic Nephropathy | - | - |
MAS825 | Phase 2 | Coronary Heart Disease | - | - |
DNK333 5 mg | Phase 2 | Pruritus in Patients With Atopic Dermatitis | - | - |
ECMPS-IEM | Phase 2 | Detection Accuracy | - | - |
MCS110 | Phase 2 | Triple Negative Breast Cancer | - | - |
influenza vaccine | Phase 2 | Influenza | - | - |
QAX576 | Phase 2 | Allergic Rhinitis | - | - |
LCI699 | Phase 2 | Hypertension | - | - |
LYS006 20 mg | Phase 2 | Inflammatory Acne | - | - |
AEE788 | Phase 2 | Glioblastoma Multiforme | - | - |
Cryptosporidium parvum oocysts (ABO809) | Phase 2 | Cryptosporidiosis | - | - |
AQW051 | Phase 2 | Schizophrenia | - | - |
Clozapine | Phase 2 | Schizophrenia | - | - |
HSC835 | Phase 2 | Single Umbilical Cord Blood Transplantation | - | - |
QMF149 | Phase 2 | COPD | - | - |
DFV890 | Phase 2 | Symptomatic Knee Osteoarthritis | - | - |
TCH346 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CAD106 | Phase 2 | Alzheimer Disease | - | - |
Trivalent influenza virus vaccine (TIV) | Phase 2 | Human Influenza | - | - |
TIV | Phase 2 | Human Influenza | - | - |
LDK378 | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
DNK333 | Phase 2 | Irritable Bowel Syndrome | - | - |
rapcabtagene autoleucel | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Tacrolimus (Tac) | Phase 2 | Kidney Transplantation | - | - |
Serelaxin | Phase 2 | Acute Heart Failure | - | - |
AF056 | Phase 2 | Fragile X Syndrome | - | - |
AHU377 | Phase 2 | Systolic Hypertension | - | - |
LDE225 | Phase 2 | Medulloblastoma | - | - |
LIK066 | Phase 2 | Polycystic Ovary Syndrome | - | - |
LEE011 | Phase 2 | Tumors With CDK4/6 Pathway Activation | - | - |
CMK389 | Phase 2 | Pulmonary Sarcoidosis | - | - |
Investigational Treatment | Phase 2 | Actinic Keratosis | - | - |
AEB071 | Phase 2 | Kidney Transplantation | - | - |
crizanlizumab | Phase 2 | Sickle Cell Disease (SCD) | - | - |
TKI258 | Phase 2 | Melanoma | - | - |
LDE225 0.25% | Phase 2 | Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients | - | - |
CDZ173 | Phase 2 | Primary Sjögren's Syndrome | - | - |
AAE581 | Phase 2 | Osteoporosis | - | - |
Mometasone furoate | Phase 2 | Asthma | - | - |
Monovalent inactivated influenza vaccine | Phase 2 | Prepandemic Influenza Vaccine | - | - |
Seasonal flu vaccine | Phase 2 | Seasonal Influenza | - | - |
Triamcinolone acetonide | Phase 2 | Acute Gout | - | - |
Investigational new drug, company code: BGG492 | Phase 2 | Seizures | - | - |
PKN605 | Phase 2 | Atrial Fibrillation | - | - |
rapcabtagene autoleucel (YTB323) | Phase 2 | Relapsing Multiple Sclerosis | - | - |
Deferasirox (ICL670) | Phase 2 | Iron Overload | - | - |
Atrasentan | Phase 2 | IgA Nephropathy | - | - |
AFQ056 | Phase 2 | Dyskinesias | - | - |
YTB323 | Phase 2 | Systemic Lupus Erythematosus | - | - |
TOUR006 - 20 MG | Phase 2 | Thyroid Eye Disease | - | - |
TIN816 70 mg lyophilisate powder | Phase 2 | Acute Kidney Injury Due to Sepsis | - | - |
N-acetylcysteine | Phase 2 | Common Cold Associated With Cough | - | - |
epothilone b | Phase 2 | Colorectal Neoplasms | - | - |
ICL670 | Phase 2 | Sickle Cell Disease | - | - |
buparlisib | Phase 2 | Breast Cancer | - | - |
JSB462 | Phase 2 | Metastatic Hormone-sensitive Prostate Cancer | - | - |
JDQ443 | Phase 2 | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | - | - |
Everolimus and Intravesical Gemcitabine | Phase 2 | Bladder Cancer | - | - |
H5N1 influenza vaccine | Phase 2 | Avian Influenza | - | - |
PTK787 | Phase 2 | Prostate Cancer | - | - |
QCZ484 | Phase 2 | Hypertension (HTN) | - | - |
AUY922 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
bimagrumab | Phase 2 | Muscle Wasting (Atrophy) After Hip Fracture Surgery | - | - |
[177Lu]Lu-PSMA-617 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
KAE609 | Phase 2 | Malaria | - | - |
SBR759 | Phase 2 | Chronic Kidney Disease | - | - |
Investigator choice of chemotherapy | Phase 2 | Nasopharyngeal Carcinoma | - | - |
LAG525 | Phase 2 | Melanoma | - | - |
STI571 | Phase 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | - | - |
Surface Antigen, Inactivated, Influenza (form.2006-07) | Phase 2 | Influenza | - | - |
QGE031 | Phase 2 | Asthma | - | - |
BYM338 | Phase 2 | Sporadic Inclusion Body Myositis | - | - |
CJM112 | Phase 2 | Asthma | - | - |
LCL161 | Phase 2 | Breast Cancer | - | - |
CFZ533 | Phase 2 | Sjögren Syndrome | - | - |
BGG492 | Phase 2 | Adrenocortical Adenoma | - | - |
Dovitinib (TKI258) | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
GIA632 | Phase 2 | Non-segmental Vitiligo | - | - |
rMenB | Phase 2 | Meningococcal Disease | - | - |
Patupilone | Phase 2 | Hepatocellular Carcinoma | - | - |
QBW251 | Phase 2 | Chronic Obstructive Pulmonary Disease, COPD | - | - |
DJI136 | Phase 2 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | - | - |
AIN457A | Phase 2 | Psoriatic Arthritis | - | - |
Crizanlizuamb | Phase 2 | Sickle Cell Disease (SCD) | - | - |
RAD001 (everolimus) | Phase 2 | Small Cell Lung Cancer | - | - |
PDR001 | Phase 2 | Small Cell Lung Cancer | - | - |
VHB937 | Phase 2 | Alzheimer's Disease | - | - |
KAF156 | Phase 2 | Malaria | - | - |
Gleevec | Phase 2 | Prostate Cancer | - | - |
LHW090 | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
Adjuvanted H5N1 pandemic influenza vaccine | Phase 2 | Pandemic H5N1 Influenza | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NOVARTIS AG's drug pipeline?→
CatalystAlert tracks 276 drug candidates in NOVARTIS AG's (NVSEF) pipeline across Phase 3, Phase 2. Its lead program is Indacaterol 150 µg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NOVARTIS AG's next FDA catalyst?→
NOVARTIS AG's (NVSEF) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NVSEF biotech catalysts?→
Add NVSEF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NOVARTIS AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.